Markets

Sanofi's Brivekimig Shows Efficacy In Biologic-Naïve HS Patients In Phase 2a Study

September 17, 2025 — 01:33 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Sanofi (SNY) announced promising new data from its HS-OBTAIN phase 2a study, highlighting the efficacy of brivekimig in treating biologic-naïve patients with moderate-to-severe hidradenitis suppurativa (HS).

At week 16, brivekimig demonstrated clinically meaningful improvements in both the primary endpoint—Hidradenitis Suppurativa Clinical Response (HiSCR50)—and key secondary endpoints compared to placebo. The treatment was well tolerated, with no serious adverse events reported. These findings will be presented in an oral session at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris.

Hidradenitis suppurativa is a chronic and debilitating inflammatory skin disease characterized by painful cutaneous nodules, abscesses and draining tunnels.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Sanofi's Brivekimig Shows Efficacy In Biologic-Naïve HS Patients In Phase 2a Study

Tags

Latest Articles